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Abstract Estrogen receptor K (ERK)-negative breast cancer
cells display an aggressive phenotype. We previously showed
that adenoviral expression of ERK in ER-negative breast cancer
cells leads to an estrogen-dependent down-regulation of the pro-
liferation, which could be of interest to control the growth of
such cells. In this study, we observed an increase in protein
levels of p21 and p27 cyclin-dependent kinase inhibitors, where-
as pRb phosphorylation is strongly decreased. Flow cytometry
experiments showed a slower transit of cells in G1 (hormone-
independent), a hormone-induced accelerated transit through
S phase and a possible arrest in G2/M phase. In addition, ERK-
expressing cells were undergoing apoptosis. By using cDNA
macroarrays, we identi¢ed a novel collection of genes regulated
by liganded ERK potentially regulating cell cycle, apoptosis, cell
signalling, stress response and DNA repair.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Breast cancer is one of the leading causes of premature
death in women in western countries [1]. Increased lifetime
exposure to estrogens is an established risk factor for develop-
ment of breast cancer. Estrogen action is mediated by two
estrogen receptors, ERK and ERL. ERL is poorly expressed
in breast tumors [2]. A high percentage of early stage mam-
mary tumors are ERK-positive and about 50% of these pa-
tients respond to anti-estrogen or endocrine therapy [3,4].
Later stages of breast cancer are more aggressive and refrac-
tory to most therapies and this correlates with the ERK-neg-
ative phenotype of these tumors [5]. ERK-positive tumor cells
are poorly metastatic in nude mice when compared with some
ERK-negative breast cancer cells [6]. In patients, ERK-positive
tumors are more di¡erentiated and have lower metastatic po-
tential than ERK-negative tumors [7], suggesting a protective
role of ERK in tumor progression. Introduction of ERK into
ER-negative breast cancer cells has been thought to provide a
rational basis for converting anti-estrogen-resistant cells to
hormonal manipulation. However, in contrast to the expected
stimulated proliferation of ER-positive cells by estradiol, the
restoration of ERK expression in ER-negative breast cancer
cells leads to a ligand-dependent inhibition of proliferation as
shown by numerous studies [8^11]. The mechanisms under-
lying this phenomenon have been poorly investigated and
could be of great interest to control the proliferation of these
aggressive types of tumor cells. The goal of this study was to
discern events responsible for the ligand-dependent inhibition
of breast cancer cells expressing exogenously ERK by analyz-
ing possible cell cycle regulation and modulation of gene ex-
pression.
2. Materials and methods
2.1. Recombinant adenovirus construction and propagation
The complete coding sequence of wild-type hERK cDNA was sub-
cloned in BamHI site of the pACsk12CMV5 shuttle vector. To obtain
recombinant viruses, permissive HEK-293 cells (human embryonic
kidney cells) were cotransfected with the backbone or recombinant
pACsk12CMV5-hER plasmid and with pJM17, which contains the
remainder of the adenoviral genome as previously described [11]. In
vivo recombination of the plasmids generates infectious viral particles
Ad5 (backbone virus) and Ad-hERK. Titered virus stocks were used
to infect MDA-MB-231 cells.
2.2. Cell culture and infection
MDA-MB-231 cells were maintained in Leibovitz L-15 medium
supplemented with 10% fetal calf serum (FCS) and gentamicin. To
wean the cells o¡ steroids, they were cultured in phenol red-free Dul-
becco’s modi¢ed Eagle’s medium/F12 supplemented with 10% char-
coal dextran-treated FCS for 4 days. For infection, cells were cultured
in the same medium and infected with Ad5 or Ad-hERK viruses at a
multiplicity of infection of 100.
2.3. Whole cell extract preparation and Western blot
Cell extracts were prepared in NP40 bu¡er (50 mM Tris^HCl pH
8.0, 150 mM NaCl, 1% NP40, 10 WM sodium £uoride, 0.1 mM so-
dium orthovanadate, 1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml
aprotinin, leupeptin, pepstatin A and 20 nM okadaic acid). Cells were
washed twice in ice-cold phosphate-bu¡ered saline (PBS), scraped in
ice-cold NP40 bu¡er and lysed for 10 min. Cell lysates were cleared by
a 15 min centrifugation at 4‡C, protein content in the supernatant was
assayed by the Bradford protein assay (Bio-Rad). The cell extracts
were diluted 1:1 in 2ULaemmli sample bu¡er, followed by boiling for
5 min. Equal amounts of protein were loaded and separated for so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis gel. Proteins
were transferred to cellulose nitrate ¢lters (Schleicher and Schuell,
Germany) and blocked for 30 min at 37‡C in 5% non-fat milk in
TBST (Tris-bu¡ered saline with 0.1% Tween 20). Membranes were
incubated with the primary antibody for 1 h at room temperature
in TBST. The primary antibodies were: cdc2 (Ab-4; NeoMarkers)
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1:500; cdk2 (Transduction Laboratories) 1:1000; Cyc A (BF683;
Santa Cruz Biotechnology) 1:200; Cyc B1 (GNS1; Santa Cruz Bio-
technology) 1:200; Cyc D1 (CDS6, Sigma) 1:200; Cyc D3 (Trans-
duction Laboratories) 1:1000; Cyc E (M20; Santa Cruz Biotechnol-
ogy) 1:200; ERK (ER-311 [12]) 1:1000; ERK (K23; Santa Cruz
Biotechnology) 100 Wg/ml; Rb (IF8; Santa Cruz Biotechnology)
1:500; p21CIP1 (L17; Santa Cruz Biotechnology) 1:100; p27Kip1
(C19; Santa Cruz Biotechnology) 1:100. After washing, horseradish
peroxidase-linked secondary antibodies (Amersham Pharmacia) were
added and target protein bands were detected using ECL (Amersham
Pharmacia).
2.4. Flow cytometry experiments
To analyze the e¡ects of recombinant viruses on the cell cycle,
MCF-7 cells were infected with the adenoviral vectors, and cells
were ¢xed in 75% ethanol for 2 min. Fixed cells were then stained
with PBS containing 40 Wg/ml propidium iodide and 100 Wg/ml
RNase. After a 30 min incubation at 37‡C, analysis was performed
on an Epics-XL £ow cytometer (Beckman Coulter, Fullerton, CA,
USA) and analyzed with Mod¢t software (Verity Software, Topsham,
ME, USA).
2.5. RNA extraction, Northern blot and cDNA microarrays
Total RNA was isolated with TRIzol reagent (InVitrogen) as de-
scribed by the manufacturer. RNA quantity was determined photo-
metrically by absorption at 260 nm and quality was checked by ex-
amination of the 28S and 18S rRNA bands in ethidium bromide-
stained agarose gels. After two phenol/chloroform extractions, RNA
was precipitated. To remove genomic DNA contamination, RNA was
treated with RNase-free DNase I (Clontech, Palo Alto, CA, USA),
and was then dissolved in RNase-free H2O and stored at 380‡C until
analysis. For Northern blot analysis, 20 Wg RNA was electrophoresed
and then hybridized with the di¡erent probes. The Atlas human mac-
roarray (7740-1: 588 genes) was purchased from Clontech. For cDNA
probes, 5 Wg of total RNA from MDA-MB-231 infected with Ad-
hERK and treated or not for 24 h with E2 (1038 M) was used. The
Atlas arrays were then hybridized with the probes according to the
manufacturer’s instructions. Array images were analyzed using Atlas
Image 2.0 software (Clontech). The cut-o¡ for cDNA array screening
was set to 2.0-fold change for up-regulated genes and to 0.4-fold
change (60% decrease) for down-regulated genes.
3. Results
3.1. Growth inhibition involves G2/M transition blockage
We have previously shown that exogenous expression of
ERK in MDA-MB-231 ER-negative breast cancer cells leads
to growth inhibition in the presence of estradiol [11]. To better
characterize the phenomenon involved in growth inhibition,
we performed £ow cytometry experiments on cells which had
been treated for di¡erent times with estradiol (Fig. 1). Cell
cycle distribution of Ad5-infected cells remained unchanged
upon estrogen treatment. On the other hand, introduction
of hERK in MDA-MB-231 cells led to both ligand-indepen-
dent and ligand-dependent changes in the cell cycle. An accu-
mulation of cells in G1 phase was observed in a ligand-inde-
pendent manner in hERK-expressing cells compared to Ad5-
infected cells. Upon treatment with estradiol, the proportion
of ERK-positive cells in S phase was strongly diminished
(from 27 to 16%). The proportion of cells in G2/M phase,
which was strongly reduced after ERK introduction, increased
from 13 to 17% following E2 addition. Importantly, we also
detected the presence of a sub-G1 peak in Ad-hERK cells
(representing around 1.5% of total cells in the absence of
estradiol), which is characteristic of cells undergoing apoptosis
(Fig. 1). This peak reached its maximum in Ad-hERK-infected
cells treated for 4 h with E2, with 3.8% apoptotic cells, where-
as Ad5-infected cells displayed less than 0.5% apoptotic cells.
3.2. Analysis of cell cycle modulator expression
To dissect the mechanisms underlying this inhibition of
proliferation, we analyzed at the protein level the expression
of a collection of known cell cycle modulators. A time course
treatment with estradiol was performed on Ad5- or Ad-
hERK-infected cells and whole cell extracts were analyzed
by Western blot (Fig. 2). The presence of ERK was only
detected in Ad-hERK-infected cells. In addition, the appear-
ance of a slower migrating band upon estradiol treatment
could correspond to a phosphorylated form of ERK. We ob-
served both ligand-dependent and ligand-independent changes
in cycle modulator expression. Cyclins D1 and E were up-
regulated and cyclin A down-regulated in a ligand-indepen-
dent manner. ERK phosphorylation did not show signi¢cant
modi¢cation, whereas pRb phosphorylation was strongly di-
minished in a ligand-dependent manner. The cyclin-dependent
kinase inhibitors (CDKIs) p21 and p27 showed a nice up-
regulation following estradiol treatment. Finally, cyclin D3,
cdc2 and cdk2 levels were stable. In summary, these data
show a complex regulation of cyclins and CDKI involved in
G1 to S phase transition.
3.3. Liganded ERK induces a complex pattern of gene
regulation
To further characterize the mechanisms underlying the
growth inhibitory e¡ect of liganded ERK, we compared the
expression of 588 genes between ERK-infected cells treated or
not with E2, by using cDNA macroarrays. A total of 13 genes
were up-regulated by E2 (Table 1), whereas 26 genes were
down-regulated by E2 (Table 2). The genes identi¢ed were
potentially involved in oncogenesis or tumor suppression
(RAF, c-myc, c-fms, c-jun, Fra-1, Axl), cell cycle (cyclin G2,
Table 1
Genes up-regulated by E2 in Ad-hERK-infected MDA-MB-231 cells
GenBank accession number Gene name Fold change Putative function
X03484 RAF 2.4 Oncogenes ^ tumor suppressors/intracellular kinase network members
U47414 Cyclin G2 2.3 Cell cycle/cyclins
D38305 TOB 3.1 Cell cycle/adapters and receptor-associated proteins
U15174 BNIP3 3.2 Apoptosis/Bcl2 family proteins
S40706 GADD153 2.1 Apoptosis/DNA damage
U09579 p21/CIP-1 15.8 Cell cycle/CDK inhibitors
U30504 TAFII31 2.0 Transcription/RNA polymerase
K03222 TGFK 11.4 Cell signalling ^ extracellular communication proteins/growth factors
X03438 G-CSF 12.3 Cell signalling ^ extracellular communication proteins/cytokines
M16552 Thrombomodulin 6.2 Cell signalling ^ extracellular communication proteins/growth factors
D30751 BMP-4 4.8 Cell signalling ^ extracellular communication proteins/growth factors
X70326 Macmarcks 2.9 Intracellular transducers/kinase activators and inhibitors
K02770 IL-1L 18.5 Cell signalling ^ extracellular communication proteins/cytokines
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Fig. 1. ERK blocks cell cycle. Ad5- or Ad-hERK-infected MDA-MB-231 cells which had been treated for 0, 4, 24 or 48 h with E2 1038 M were analyzed by £uorescence-activated cell sorting
(FACS) for cell cycle distribution. A: Representative pro¢les of FACS analysis. B: Quanti¢cation of cell cycle distribution.
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Fig. 2. Modulation of cell cycle regulatory factors by ERK. Whole cell extracts from Ad5- or Ad-hERK-infected MDA-MB-231 cells which had
been treated for 0^48 h with E2 (1038 M) were used for determination of the expression of ERK, Erk, cyclin D1, cyclin D3, cyclin E, cyclin A,
p21CIP1, p27Kip1, cdk2, cdc2 and pRb by Western blot.
Table 2
Genes down-regulated by E2 in Ad-hERK-infected MDA-MB-231 cells
GenBank accession
number
Gene name Fold change Putative function
V00568 c-myc 0.2 Oncogenes ^ tumor suppressors/transcription activators and repressors
X03663 c-fms 0.3 Oncogenes ^ tumor suppressors/intracellular transducers
J04111 c-jun 0.1 Oncogenes ^ tumor suppressors/transcription activators and repressors
X16707 Fra-1 0.1 Oncogenes ^ tumor suppressors/transcription activators and repressors
M76125 Axl 0.6 Oncogenes ^ tumor suppressors/intracellular transducers
U02687 STK-1 0.5 Cell cycle/intracellular transducers
M62424 Thrombin receptor 0.3 Intracellular transducers/growth factor receptors
M31630 ATF-2 0.5 Transcription activators and repressors/intracellular transducers
M34664 HSP60 0.6 Stress response proteins/heat shock proteins
X15722 Glutathione reductase 0.1 Stress response proteins/xenobiotic transporters
M21304 Glutathione peroxidase (GPX1) 0.4 Stress response proteins/xenobiotic transporters
U18321 DAP-3 0.6 Apoptosis
J04088 TopoIIK 0.2 DNA synthesis ^ recombination and repair/topoisomerases
D21235 HHR23A 0.4 DNA synthesis ^ recombination and repair/nucleotide excision repair
D21090 HHR23B 0.4 DNA synthesis ^ recombination and repair/nucleotide excision repair
M60974 Gadd45 0.5 Apoptosis/DNA synthesis ^ recombination and repair
U35835 DNA-PK 0.4 DNA synthesis ^ recombination and repair/stress response proteins
L34673 HIP116 0.2 Transcription/basic transcription factors
D90209 ATF-4 0.2 Transcription/transcription activators and repressors
M28372 CNBP 0.1 Transcription/basic transcription factors
M83234 Y-box protein 0.4 Transcription/basic transcription factors
M59911 Integrin K-3 chain 0.6 Cell adhesion proteins/cell^cell adhesion receptors
X07979 Integrin L1 subunit 0.4 Cell adhesion proteins/cell^cell adhesion receptors
M92934 CTGF 0.1 Cell signalling ^ extracellular communication proteins/growth factors
M14200 DBI/ACBP 0.6 Metabolism/nucleotide metabolism
M31159 IGFBP-3 0.4 Cell signalling ^ extracellular communication proteins/hormones
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TOB, p21, STK-1), apoptosis (BNIP3, Gadd45, Gadd153,
DAP-3), transcription (TAFII31, ATF-2, ATF-4, HIP116,
CNBP, Y box), cell signalling (TGFK, G-CSF, thrombo-
modulin, BMP-4, IL-1L, thrombin receptor, Macmarcks,
CTGF), cell adhesion (integrin K3 chain, integrin L1 subunit),
stress response (HSP60, glutathione reductase, glutathione
peroxidase), DNA synthesis and repair (TopoIIK, HHR23A,
HHR23B, DNA-PK, DBI). This suggests that exogenous ex-
pression of ERK and subsequent activation by E2 lead to
major changes in gene regulation of the cells a¡ecting multiple
aspects of cell life.
3.4. Con¢rmation of the regulations by Northern blot
To con¢rm the regulations identi¢ed by cDNA array
screening, we analyzed the expression of 13 genes by Northern
blot (Fig. 3). The pS2 gene (not present on the array), which is
a marker of estrogen receptor function [13], was used as a
positive control of estrogen regulation and expressed only in
Ad-ERK-infected cells treated with E2. DAP-3 levels were
down-regulated by ERK in a ligand-independent manner.
We observed that the levels of Fra-1, Gadd45 and TopoIIK
and to a minor extent DNA-PK were e¡ectively down-regu-
lated by liganded-ERK, whereas G-CSF, IL-1L, Macmarcks,
BNIP3, p21/CIP-1 and TGFK levels were up-regulated, which
validates our screen. Cyclin G2 was up-regulated by E2 in
ERK-expressing cells and to a minor extent in Ad5-infected
cells. This could be due to the low levels of endogenous ERK
and ERL in these cells.
4. Discussion
To identify the mechanisms underlying cell growth inhibi-
tion triggered by liganded ERK in ER-negative breast cancer
cells, we have analyzed cell cycle distribution and gene expres-
sion changes. Our results suggest that introduction of ERK in
ER-negative cells leads to both ligand-independent and li-
gand-dependent modi¢cations. Expression of exogenous
ERK induces changes in cell cycle kinetics characterized by
a slower transit of cells in G1 (independent of hormone)
and an accelerated cell exit from the S phase (hormone-in-
duced) with a possible bottleneck of the cycle in G2/M. Ap-
optosis, on the other hand, appears to be promoted by hor-
mone-activated ER. We should point out that previous work
from our group [11] has shown an increase of cell size, when
they were infected by Ad-hERK and treated with E2. This
could re£ect cell blockage in G2/M and appearance of cells
with high DNA content.
Ligand-dependent modi¢cation of the cell cycle is concom-
itant with an up-regulation of p21, p27, Macmarcks and TOB
levels, a down-regulation of STK1 expression and a dephos-
phorylation of pRb. p21, p27, TOB, Macmarcks and cyclin
G2 have been shown to inhibit proliferation [14^17], whereas
STK1 overexpression could increase proliferation [18]. The
down-regulation of Gadd45, whose expression is frequently
increased in growth-arrested cells and regulated by BRCA-1
[19], might be explained by the down-regulation of BRCA-1
we observed previously in such infected cells [20]. On the
other hand, apoptosis is occurring as shown by the appear-
ance of a sub-G1 peak and induction of pro-apoptotic BNIP3
[21]. It is also interesting to note that several oncogenes such
as c-myc, c-fms, c-jun, Fra-1, Axl, or transcription factors
such as ATF-2, ATF-4, HIP116, CNBP or Y box are down-
regulated. All these proteins generally promote tumorigenesis
[22^27]. Abnormal expression of c-fms, Axl, members of the
AP-1 family, CNBP (which stimulates c-myc promoter activ-
ity) or Y box protein by malignant cells is correlated with a
poor prognosis [22^26,28].
Down-regulation of topoisomerase IIK, HHR23A,
HHR23B, DBI/ACBP and to a lesser extent DNA-PK sug-
gests that reintroduction of ERK in MDA-MB-231 cells leads
to a decreased e⁄ciency of DNA repair [29^31], which could
eventually lead to apoptosis. In addition to the weaker ability
of the cells to defend themselves against DNA damage, it is
likely that the cells are also losing their ability to respond to
Fig. 3. Analysis of a subset of genes regulated by ERK in MDA-
MB-231 cells. The expression of cyclin G2 DNA-PK, Fra-1,
Gadd45, G-CSF, IL-1L, DAP-3, Macmarcks, BNIP3, p21CIP1,
TGFK, TopoIIK and pS2 was analyzed by Northern blot using
RNA from Ad5- or Ad-hERK-infected MDA-MB-231 cells, treated
or not for 48 h with E2.
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stress signals as shown by down-regulation of HSP60, gluta-
thione peroxidase and glutathione reductase [32,33].
Overall changes in integrin and BMP-4 and ligand-indepen-
dent down-regulation of DAP-3 [34^36] could also account
for the previously observed inhibition of invasion observed
after reintroduction of ERK [9]. Other events such as down-
regulation of thrombin receptor and up-regulation of throm-
bomodulin could also account for the decreased invasiveness
of these cells [37^39]. In addition, the down-regulation of
CTGF, which promotes angiogenesis [40], suggests that
ERK exogenous expression could reduce the angiogenesis
events during tumor formation. It is also interesting to note
that the majority of the genes regulated by E2 that we dis-
covered have not been previously identi¢ed as potential tar-
gets of ER, con¢rming the importance of our screen.
In conclusion, our data suggest that reintroduction of ERK
in ER-negative breast cancer cells could be a valuable strategy
to limit their growth and their invasion. This is also concom-
itant with a reduced ability to repair damaged DNA and to
respond to stress signals, which further suggests that the cells
are more likely to lose their advantages over normal cells.
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